迪瑞医疗
(300396)
| 流通市值：37.35亿 | | | 总市值：37.39亿 |
| 流通股本：2.72亿 | | | 总股本：2.73亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 182,424,018.64 | 1,217,807,735.16 | 1,175,445,053.92 | 878,270,442.69 |
| 营业收入 | 182,424,018.64 | 1,217,807,735.16 | 1,175,445,053.92 | 878,270,442.69 |
| 利息收入 | 0 | - | - | - |
| 已赚保费 | 0 | - | - | - |
| 手续费及佣金收入 | 0 | - | - | - |
| 二、营业总成本 | 174,838,646.92 | 1,107,954,218.58 | 986,818,603.55 | 715,273,727.92 |
| 营业成本 | 104,388,815.67 | 683,955,656.48 | 665,191,024.53 | 499,767,255.82 |
| 利息支出 | 0 | - | - | - |
| 手续费及佣金支出 | 0 | - | - | - |
| 退保金 | 0 | - | - | - |
| 赔付支出净额 | 0 | - | - | - |
| 提取保险合同准备金净额 | 0 | - | - | - |
| 保单红利支出 | 0 | - | - | - |
| 分保费用 | 0 | - | - | - |
| 税金及附加 | 2,494,529.95 | 11,490,628.81 | 9,690,305.51 | 5,634,198.65 |
| 销售费用 | 40,890,892.69 | 231,537,434.1 | 177,180,126.68 | 123,253,400.43 |
| 管理费用 | 13,354,697.22 | 56,839,267.07 | 34,301,565.3 | 24,922,488 |
| 研发费用 | 21,117,372.39 | 130,431,565.75 | 95,643,187.59 | 63,079,105.67 |
| 财务费用 | -7,407,661 | -6,300,333.63 | 4,812,393.94 | -1,382,720.65 |
| 其中:利息费用 | 2,694,928.67 | 8,736,876.51 | 5,843,826.12 | 3,856,330.98 |
| 其中:利息收入 | 2,020,177.25 | 18,872,358.53 | 5,229,684.7 | 3,918,302.46 |
| 加:公允价值变动收益 | 0 | -185,848.63 | -185,848.63 | -185,848.63 |
| 加:投资收益 | 4,429,146.72 | 23,607,377.55 | 20,686,292.54 | 15,185,936.95 |
| 净敞口套期收益 | 0 | - | - | - |
| 汇兑收益 | 0 | - | - | - |
| 资产处置收益 | 134,425 | 82,446.44 | 0 | 0 |
| 资产减值损失(新) | 81,449.38 | -1,085,123.38 | -2,754,655.98 | 129,594.96 |
| 信用减值损失(新) | -711,353.55 | -11,107,671.88 | -11,883,878.16 | -12,719,287.2 |
| 其他收益 | 2,467,311.39 | 22,483,639.93 | 19,617,801.24 | 17,131,702.29 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 13,986,350.66 | 143,648,336.61 | 214,106,161.38 | 182,538,813.14 |
| 加:营业外收入 | 190,689.04 | 3,056,183.69 | 448,539.74 | 27,016.42 |
| 减:营业外支出 | 139,725.81 | 1,016,796.37 | 937,650.95 | 742,978.93 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 14,037,313.89 | 145,687,723.93 | 213,617,050.17 | 181,822,850.63 |
| 减:所得税费用 | -1,639,889.91 | 3,782,718.32 | 21,050,445.45 | 16,589,240.82 |
| 六、净利润 | 15,677,203.8 | 141,905,005.61 | 192,566,604.72 | 165,233,609.81 |
| 持续经营净利润 | 15,677,203.8 | 141,905,005.61 | 192,566,604.72 | 165,233,609.81 |
| 终止经营净利润 | 0 | - | - | - |
| 归属于母公司股东的净利润 | 15,678,683.66 | 141,922,552.76 | 192,577,440.82 | 165,242,953.91 |
| 少数股东损益 | -1,479.86 | -17,547.15 | -10,836.1 | -9,344.1 |
| (一)基本每股收益 | 0.06 | 0.52 | 0.71 | 0.61 |
| (二)稀释每股收益 | 0.06 | 0.52 | 0.71 | 0.61 |
| 八、其他综合收益 | 5,330,335.74 | 3,902,996.17 | 867,601.54 | 1,144,923.19 |
| 归属于母公司股东的其他综合收益 | 5,330,156.79 | 3,903,295.08 | 867,496.48 | 1,146,578.92 |
| 九、综合收益总额 | 21,007,539.54 | 145,808,001.78 | 193,434,206.26 | 166,378,533 |
| 归属于母公司股东的综合收益总额 | 21,008,840.45 | 145,825,847.84 | 193,444,937.3 | 166,389,532.83 |
| 归属于少数股东的综合收益总额 | -1,300.91 | -17,846.06 | -10,731.04 | -10,999.83 |
| 公告日期 | 2025-04-26 | 2025-03-29 | 2024-10-25 | 2024-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |